Zosuquidar (LY335979) 3HCl: Precision P-gp Inhibitor for Cancer MDR Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent, selective inhibitor of the P-glycoprotein (P-gp) efflux pump, a crucial driver of multidrug resistance (MDR) in cancer (Sun et al., 2025). At low micromolar concentrations, Zosuquidar restores sensitivity to standard chemotherapeutics in P-gp overexpressing models. In vivo, it enhances antitumor activity and survival in MDR leukemia and carcinoma models without affecting chemotherapeutic pharmacokinetics. Phase I/II clinical trials show effective P-gp inhibition with minimal toxicity. The compound, available from APExBIO as product A3956, provides a robust tool for preclinical and translational research into MDR reversal.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux transporter found in tissues such as the brain, liver, intestine, and cancer cells (Sun et al., 2025). P-gp exports structurally diverse xenobiotics, including chemotherapeutic agents, reducing intracellular drug accumulation. Overexpression of P-gp is a key mechanism of multidrug resistance (MDR) in oncology, particularly in acute myeloid leukemia (AML), non-Hodgkin’s lymphoma, and solid tumors [internal]. The clinical challenge is to selectively inhibit P-gp to restore chemosensitivity without broad off-target toxicity. Zosuquidar (LY335979) 3HCl addresses this by offering high selectivity and potency for P-gp over other ABC transporters.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar acts as a competitive inhibitor of P-gp, binding to the substrate recognition site and blocking the efflux of chemotherapeutic drugs such as vinblastine, doxorubicin, etoposide, and paclitaxel (APExBIO product data). In vitro studies reveal that Zosuquidar restores drug accumulation in P-gp overexpressing cells at concentrations as low as 0.1–1 μM. The specificity is due to its unique chemical structure: (2R)-1-(4-((1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol. This compound does not inhibit other major efflux pumps (e.g., MRP1, BCRP) at active concentrations (Sun et al., 2025). Zosuquidar prolongs cytotoxic drug retention, thereby restoring apoptosis induction in MDR cells. It does not significantly alter the pharmacokinetics of co-administered drugs in murine and human models, reducing risk of drug-drug interactions.

Evidence & Benchmarks

• Zosuquidar at 0.5–1 μM restores sensitivity of P-gp overexpressing leukemia cell lines to vinblastine and doxorubicin in vitro (IC50 reductions >10-fold) (Sun et al., 2025).
• In murine MDR leukemia models, co-administration of Zosuquidar (5 mg/kg, i.p.) with doxorubicin increases survival by 40% compared to doxorubicin alone (Sun et al., 2025).
• In vivo studies confirm that Zosuquidar does not significantly alter plasma pharmacokinetics (AUC, Cmax) of paclitaxel or etoposide (dose-matched, n=6 mice per group) (Sun et al., 2025).
• Phase I/II clinical trials in non-Hodgkin's lymphoma (CHOP ± Zosuquidar) show complete P-gp inhibition in peripheral blood lymphocytes at plasma levels >500 ng/mL with minimal added toxicity (APExBIO).
• Multiple dosing and tissue distribution studies reveal that P-gp inhibition by Zosuquidar increases drug accumulation specifically in liver and tumor tissues, with no significant increase in off-target organs (Sun et al., 2025).

This article extends previous coverage by integrating clinical trial outcomes and pharmacokinetic data not included in "Zosuquidar (LY335979) 3HCl: Next-Generation P-gp Inhibition", providing a translational bridge from bench to bedside. For mechanistic depth, see "P-Glycoprotein Modulation in Cancer: Mechanistic Advances", which this article updates with new in vivo and clinical findings.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl, available as product A3956 from APExBIO, is applied in:

• Reversing MDR in P-gp overexpressing cancer models (leukemia, lymphoma, solid tumors).
• Pharmacokinetic studies to assess transporter-drug interactions.
• Enhancing cytotoxicity of standard chemotherapeutics in vitro and in vivo.
• Clinical trial regimens for combinatorial chemotherapy sensitization.

Common Pitfalls or Misconceptions

• Not effective against non-P-gp MDR: Zosuquidar does not inhibit other efflux pumps (e.g., MRP1, BCRP) at active concentrations.
• Species-specific transporter differences: Rodent P-gp isoforms may differ in inhibitor sensitivity; always validate in human cells.
• Does not intrinsically induce cytotoxicity: Zosuquidar is not cytotoxic at relevant doses in most cell models.
• Limited solubility/stability in aqueous buffers: Solutions should be prepared in DMSO and freshly diluted; long-term storage of solutions is not recommended (APExBIO).
• Does not reverse resistance mediated by drug metabolism or non-P-gp mechanisms: MDR due to CYP450 induction or mutation-driven mechanisms is not addressed.

Workflow Integration & Parameters

Formulation: Zosuquidar (LY335979) 3HCl is soluble in DMSO (≥10 mM). Prepare aliquots and store at –20°C. Avoid repeated freeze-thaw cycles.
In vitro use: Typical concentrations: 0.1–2 μM. Add directly to cell culture media (final DMSO ≤0.1%).
In vivo use: Dosing regimens in mice: 2.5–10 mg/kg, intraperitoneal injection, once daily or per experimental protocol.
Clinical translation: Plasma levels >500 ng/mL are required for full P-gp inhibition; confirm with functional assays.
Quality control: Verify compound identity by mass spectrometry (MW 527.6, CAS 167354-41-8).

For advanced applications, including troubleshooting and protocol optimization, see "Zosuquidar (LY335979) 3HCl: P-gp Inhibitor for Multidrug Resistance". This article adds updated clinical and tissue distribution parameters.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is the reference standard for selective P-glycoprotein inhibition in multidrug resistance research. Its validated efficacy in preclinical and early clinical settings, combined with favorable pharmacokinetic and safety profiles, positions it as a critical tool for translational oncology workflows. As research advances, the integration of Zosuquidar into combination regimens and personalized MDR diagnostics will further refine cancer therapy. For full specifications and ordering, see the APExBIO A3956 product page.